CING (Cingulate) Change In Receivables: $-0.01 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CING Cingulate Inc CING
36 GF Score
Price $4.54
! 1 Warning Sign
View Full Analysis

What is Cingulate Change In Receivables?

Cingulate CING +2.48% 36 Change In Receivables is $-0.01 Mil as of Mar. 2026. GuruFocus rates CING with a GF Score™ of 36/100. The stock has 1 warning sign investors should review.

Cingulate's change in receivables for the quarter that ended in Mar. 2026 was $-0.05 Mil. It means Cingulate's Accounts Receivable increased by $0.05 Mil from Dec. 2025 to Mar. 2026 .

Cingulate's change in receivables for the fiscal year that ended in Dec. 2025 was $0.02 Mil. It means Cingulate's Accounts Receivable declined by $0.02 Mil from Dec. 2024 to Dec. 2025 .

Cingulate's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cingulate's liquidation value for the three months ended in Mar. 2026 was $13.90 Mil.

Cingulate  (NAS:CING) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cingulate's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Cingulate's accounts receivable are only considered to be worth 75% of book value:

Cingulate's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=25.893-11.997+0.75 * 0+0.5 * 0
=13.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cingulate Change In Receivables Related Terms

Cingulate Change In Receivables Historical Data

* Premium members only.

The historical data trend for Cingulate's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cingulate Change In Receivables Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -0.54 0.46 0.22 -0.01 0.02

Cingulate Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.02 0.00 0.01 -0.05
CING
36GF Score
Cingulate Inc CING
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cingulate Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.01 Mil mean?
Cingulate (CING) has a Change In Receivables of $-0.01 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Cingulate and its competitors.
Is Cingulate's Change In Receivables too high?
Cingulate's current Change In Receivables is $-0.01 Mil. Overall, Cingulate has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's Change In Receivables compare to IMA and MCRB?
Cingulate's Change In Receivables of $-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Cingulate and its competitors. Cingulate's current Change In Receivables is $-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current Change In Receivables of $-0.01 Mil. The current Change In Receivables is $-0.01 Mil. Cingulate's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Cingulate (CING), the current Change In Receivables is $-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
36GF Score

Get the complete analysis for CING

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.54
Price